Article
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
The Cochrane database of systematic reviews - 25 May 2016
Greenhalgh Janette, Dwan Kerry, Boland Angela, Bates Victoria, Vecchio Fabio, Dundar Yenal, Jain Pooja, Green John A
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) mutation positive (M+) non-small cell lung cancer (NSCLC) is emerging as an important subtype of lung cancer comprising 10% to 15% of non-squamous tumours. This subtype is more common in women than men and is less associated with smoking. OBJECTIVES: To assess the clinical effectiveness of single -agent or combination EGFR therapies used in the first-line...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.